Comparative analgesic efficacy of superficial parasternal intercostal plane block versus erector spinae plane block after cardiac surgery in Türkiye: protocol for a multicentre randomised non-inferiority trial
BMJ Open, cilt.16, sa.11, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 16 Sayı: 11
- Basım Tarihi: 2026
- Doi Numarası: 10.1136/bmjopen-2026-127382
- Dergi Adı: BMJ Open
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Directory of Open Access Journals, Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest)
- Anahtar Kelimeler: Adult anaesthesia, Cardiac surgery, Pain management
- İstanbul Üniversitesi Adresli: Evet
Özet
Introduction: Median sternotomy is associated with substantial acute postoperative pain, which may impair respiratory function, delay mobilisation and increase opioid exposure. The superficial parasternal intercostal plane (SPIP) block directly targets the anterior cutaneous branches of the intercostal nerves supplying the sternotomy region, whereas the erector spinae plane (ESP) block is performed posteriorly and relies on extensive interfascial spread. Direct, adequately powered comparisons of these approaches after cardiac surgery remain limited. This trial will test whether bilateral SPIP block is non-inferior to bilateral ESP block with respect to cumulative intravenous morphine milligram equivalent (IV-MME) consumption during the first 24 hours after extubation. Methods and analysis: This multicentre, assessor-blinded, parallel-group randomised non-inferiority trial will enrol 308 adults aged 18–80 years undergoing first-time on-pump cardiac surgery through median sternotomy. Participants will be allocated 1:1, stratified by centre, to a bilateral single-shot SPIP block or a bilateral single-shot ESP block before induction of general anaesthesia. Both groups will receive a standardised perioperative anaesthetic and postoperative multimodal analgesic regimen, including intravenous patient-controlled morphine analgesia after extubation. The primary outcome is cumulative opioid consumption from extubation to 24 hours after extubation, expressed as IV-MME. The three prespecified secondary outcomes are time-weighted average pain intensity during coughing over 0–24 hours after extubation, cumulative 0–12-hour postextubation IV-MME consumption and Quality of Recovery-15 (QoR-15) scores at 24 hours after extubation. Other exploratory outcomes include resting pain, QoR-15 at hospital discharge and chronic postsurgical pain at 3 months.The primary non-inferiority analysis will be performed in both the intention-to-treat and per-protocol populations using the between-group difference in mean cumulative 24-hour IV-MME consumption, expressed as SPIP minus ESP, with a two-sided 95% CI. The primary opioid-consumption comparison will be conditional on survival through the complete assessment window. Assuming a true between-group difference of zero, a non-inferiority margin of 3 mg IV-MME, a common SD of 6.48 mg, 95% power and a one-sided α of 0.025, 123 evaluable participants per group will be required. Allowing for 20% attrition, 308 participants (154 per group) will be enrolled. Ethics and dissemination: Central ethics approval was obtained from the Ondokuz Mayıs University Clinical Research Ethics Committee (2026/392; 18 March 2026). Approval will also be obtained at each participating centre before recruitment. Written informed consent will be obtained from all participants. Results will be submitted to a peer-reviewed journal and presented at national and international scientific meetings regardless of the direction or magnitude of the findings. Trial registration number: NCT07780773.